Table 1 Baseline participants characteristics

Age, yrs

60.9 ± 10.7

61.2 ± 9. 9

60.6 ± 11.6

0.685

Male, n (%)

166 (64.1)

91 (65.0)

75 (63.0)

0.841

BMI, kg/m²

24.1 ± 3.34

24.2 ± 3.33

24.1 ± 3.37

0.828

Medical history

 Hypertension, n (%)

117 (45.2)

70 (50.0)

47 (39.5)

0.117

 Diabetes, n (%)

31 (12.0)

15 (10.7)

16 (13.4)

0.629

 CHD, n (%)

43 (16.6)

23 (16.4)

20 (16.8)

1.000

 Renal Insufficiency, n (%)

9 (3.5)

5 (3.6)

4 (3.4)

1.000

 DCM, n (%)

1 (0.4)

1 (0.7)

0 (0)

1.000

 SSS, n (%)

3 (1.2)

2 (1.4)

1 (0.8)

1.000

 Thromboembolism, n (%)

23 (8.9)

13 (9.3)

10 (8.4)

0.976

 Atrioventricular Block, n (%)

6 (2.3)

5 (3.6)

1 (0.8)

0.223

LVEF, %

62.9 ± 6.17

62.7 ± 6.52

63.1 ± 5.75

0.550

LV size, mm

44.1 ± 4.09

44.1 ± 4.19

44.1 ± 3.99

0.974

LA size, mm

41.2 ± 5.23

41.4 ± 5.33

41.0 ± 5.12

0.545

RV size, mm

29.8 ± 4.16

30.1 ± 4.04

29.4 ± 4.29

0.176

RA size, mm

37.1 ± 5.20

37.4 ± 5.54

36.8 ± 4.79

0.371

HAS-BLED

0.95 ± 1.09

0.86 ± 0.88

1.06 ± 1.28

0.022

CHA2DS2-VASc

1.79 ± 1.54

1.86 ± 1.51

1.71 ± 1.58

0.458

Anticoagulant, n (%)

< 0.001

 Dabigatran

76 (29.3)

41 (29.3)

35 (29.4)

 Warfarin

19 (7.3)

16 (11.4)

3 (2.5)

 Rivaroxaban

151 (58.3)

83 (59.3)

68 (57.1)

 Non

5 (1.9)

0 (0)

5 (4.2)

Mitral Valve, n (%)

0.206

 Normal

34 (13.1)

22 (15.7)

12 (10.1)

 Mild

205 (79.2)

110 (78.6)

95 (79.8)

 Moderate to severe

20 (7.7)

8 (5.7)

12 (10.1)

Tricuspid Valve, n (%)

0.297

 Normal

32 (12.4)

21 (15.0)

11 (9.2)

 Mild

197 (76.1)

105 (75.0)

92 (77.3)

 Moderate to severe

30 (11.6)

14 (10.0)

16 (13.4)